MC2 Therapeutics A/S: Financial statements 2019
CVR: 29526346
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
MC2 Therapeutics A/S (CVR 29526346) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 13,678,382 and a net result of DKK -81,401,184 compared with DKK -110,067,000 the year before. That is an increase of 2.5% compared with the year before. Equity in the 2019 report amounted to DKK 65,832,497. The solvency ratio was 62.3%. The company had 11 employees in the financial year.
- Gross Profit
- DKK 13,678,382
- Profit/Loss
- DKK -81,401,184
- Equity
- DKK 65,832,497
- Total Assets
- DKK 105,728,052
- Employees
- 11
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 13.7 mio. | -81.4 mio. | 65.8 mio. | 11 |
| 2018 | - | 13.3 mio. | -110.1 mio. | 62.3 mio. | 10 |
| 2017 | - | 10.3 mio. | -79.1 mio. | 30.9 mio. | 8 |
| 2016 | - | 6.8 mio. | -40.1 mio. | 54.4 mio. | 5 |
| 2015 | - | 5.4 mio. | -24.5 mio. | 43.4 mio. | 4 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
MC2 Therapeutics A/S has published its annual report for 2018. Gross profit came to DKK 13,340,000, and the net result was DKK -110,067,000.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named MC2 Therapeutics ApS and MC2 BIOTEK ApS. The management consists of Trine Ahlgreen. The board consists of Mads Jørgen Nøhr Clausen (chair), Anders Dahlgaard Hove, John Sørensen Haurum and Tomas Dahl Mikkelsen. The company is owned by Alsmark Invest II ApS, MC2 HOLDING ApS and Selskabet af 4. april 2023 ApS. The company has 8 employees (2026). In 2025, the company reported a gross profit of DKK 22,248,504 and a net result of DKK -7,816,954 compared with DKK -53,006,931 the year before. Equity in the 2025 report amounted to DKK -224,478,927.